Pomegra
Oura agreed to pay $625 million in cash for AI-native primary care startup Counsel Health, adding physician-backed medical AI to its 6 million-member smart ring business.
Key Takeaways
- Oura will pay $625M in cash for Counsel Health, with closing expected before the end of calendar 2026.
- Counsel raised about $36M in total, including a $25M Series A led by a16z and GV a year ago.
- Counsel CEO Muthu Alagappan becomes Oura's chief clinical AI officer, and 70 employees join.
Lead
Oura announced on November 10, 2026 that it will acquire Counsel Health for $625 million in cash, subject to customary purchase price adjustments. The buyer is the Finnish maker of the Oura Ring, valued at $11 billion after a $900 million round in October 2025. The target is a primary care company that pairs a chat-based medical AI with employed, board-certified physicians. The deal is expected to close before the end of 2026.
It is a strategic purchase rather than an acquihire. Oura is buying a working clinical service that has already been live inside its app since June, along with the 70-person team that runs it.
What Did Oura Agree to Pay For?
Oura is paying $625 million in cash for a company that had raised roughly $36 million in total, according to PitchBook estimates. That total comprises an $11 million seed round and a $25 million Series A led by Andreessen Horowitz and GV roughly a year ago. Counsel's last post-money valuation was not disclosed, so the step-up cannot be calculated. Against about $36 million raised, the price still stands out.
Counsel's product combines AI agents for medical history-taking, guideline retrieval and emergency detection with a physician interface called Clinician Cockpit. Licensed doctors review and supervise the output. Services include personalized medical advice, prescriptions, lab result interpretation, chronic care management and referrals.
Why Did Oura Pay So Much for a Startup This Young?
Oura paid for distribution in reverse: it already owns the data and the customer relationship, and Counsel supplies the clinical action layer. Oura's ring tracks more than 50 biometric markers, and the company says over 90% of surveyed Counsel users reported that Oura data improved their care. Counsel's care experience rating stands at 4.6 out of 5, a figure supplied by the companies.
Chairman David Shuman framed it as Oura telling members what is happening in their bodies and Counsel helping them act on it. CEO Tom Hale described a new model of care that extends the current healthcare paradigm. Those are the buyer's own words, and the numbers behind the claim are modest so far: the integration is five months old.
The financial backdrop matters. Oura reported revenue of $533 million for the quarter ended September 30, up 153% year over year, and roughly $1.75 billion for fiscal 2026, up 92%. Adjusted EBITDA for the quarter was $87 million, a 16% margin. A $625 million cash outlay is large against that profit line, though small against an $11 billion valuation.
How Does the Deal Follow Oura's Postponed IPO?
The acquisition lands weeks after Oura postponed an IPO of up to $2.2 billion on September 29, 2026, citing uncertainty in the IPO market. The company had reportedly been seeking a valuation near $15.6 billion. Spending cash on a clinical business instead of listing gives Oura a growth story that does not depend on a public market window.
It also changes what Oura's investors are being asked to value. A hardware subscription company trades on unit economics and churn. A company with a medical service attached can argue for higher revenue per member, though it also takes on clinical liability, licensing and staffing costs that a ring maker never carried.
What Does This Mean for Counsel's Existing Customers?
Counsel will keep serving its existing and new enterprise partners, according to the announcement. Those partners include health plans, health systems, digital health companies, employers and consumer health organizations. Oura says the goal is to extend the AI-native care model to people beyond its own membership.
That promise carries tension. Enterprise buyers such as health plans may hesitate to route members through a unit owned by a consumer device company with its own data interests. How Oura separates the two businesses will shape whether the enterprise line grows or shrinks.
Strategic Context
Wearable makers have spent years adding health features, but few have taken on regulated care delivery. Oura now sits closer to a vertically integrated health platform than a hardware vendor. The move puts it next to telehealth providers and AI clinical assistants that sell directly to consumers.
Execution risk is real. Primary care is staffed, licensed state by state and exposed to malpractice claims. AI-assisted triage lowers the cost per visit, but the savings depend on physician oversight ratios that the companies have not published.
Outlook
Oura gets a clinical team, a physician-supervised AI stack and a leader in Alagappan who will oversee clinical AI across the company. Counsel's investors, led by a16z and GV, get an exit about a year after a $25 million Series A. The deal is expected to close before the end of 2026, and the open questions are how many Oura members use Counsel regularly, what the service costs them, and whether Counsel's enterprise customers stay.
